1. ALLA AKTIER
  2. NYHETER
  3. MAGLE CHEMOSWED

Magle Chemoswed

Nyheter Magle Chemoswed Nyheter alla bolag

Magle Chemoswed Holding AB (publ) Releases Annual Report for 2024.

MARKN.

Magle Chemoswed Holding's Annual Report for 2024 has been published on the Group’s website as of today.

The annual report is available as a downloadable PDF document at www.maglegroup.com

"In 2024, we successfully integrated two important acquisitions into the group, Magle Biopharma and Magle Biopolymers. These two businesses, in combination with our existing operations, delivered solid revenue growth and improved the Groups profitability. This supports our ongoing commitment to delivering lasting value for our shareholders, partners, and the patients we serve," said Justin Pierce, Magle Group's CEO.

Aaron Wong, Magle Group's CFO, said, "This year’s financial results, with total revenue reaching SEK 256.2 million and a net profit of SEK 11.9 million, reflect sustained growth and underline the strength of our disciplined and strategic financial management".

Contacts Justin & Aaron

Justin Pierce, CEO, phone +46 (0)70 593 58 21, justin.pierce@maglechemoswed.com

Aaron Wong, CFO, phone +46 (0)76 664 35 79, aaron.wong@maglegroup.com

About Us

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Magle Biopolymers A/S- a specialized manufacturing organization of Dextran technology. Learn more on www.maglechemoswed.com and www.maglegroup.com and www.maglepharmacept.com and www.maglebiopolymers.com

Vator Securities is the Company's certified adviser on Nasdaq First North Growth Market and can be reached at ca@vatorsec.se or +46 (0)8-580 065 99.

Attachments

Magle Group Annual Report 2024 Final

Datum 2025-05-05, kl 17:30
Källa MFN
Bifogade filer
Magle Group Annual Report 2024 Final
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!